Emergent BioSolutions Inc. ( NYSE:EBS – Get Rating ) – Investment analysts at Cantor Fitzgerald decreased their FY2023 EPS estimates for Emergent BioSolutions in a research note issued to investors on Wednesday, March 1st. Cantor Fitzgerald analyst B. Folkes now forecasts that the biopharmaceutical company will earn ($1.52) per share for the year, down from their prior estimate of $0.35. The consensus estimate for Emergent BioSolutions' current full-year earnings is $0.40 per share. A number of other research firms have also recently issued reports on EBS.

https://www.dailypolitical.com/2023/03/03/equities-analysts-set-expectations-for-emergent-biosolutions-inc-s-fy2023-earnings-nyseebs.html

#dailypolitical